Pfizer mRNA flu shot outperforms traditional vaccine in trial
Pfizer's mRNA flu vaccine shows 34.5% fewer illnesses than traditional shots in Phase 3 trial.
Why it matters
- mRNA technology improves flu protection.
- Faster production could lead to better strain matching each year.
By the numbers
- Trial included over 18,000 adults.
- mRNA vaccine showed 34.5% fewer flu-like illnesses.
- 57 cases in mRNA group vs. 87 in traditional group.
The big picture
- mRNA vaccine could be a game-changer.
- Approval might be challenging due to skepticism and funding cuts.
What they're saying
- Dr. Buddy Creech called it a "game-changer."
- Dr. Peter Hotez expressed concern about lack of interest in mRNA science.
Caveats
- More side effects with mRNA vaccine (e.g., 5.6% fever vs. 1.7%).
- Approval may face hurdles due to funding cuts and skepticism.
What’s next
- Pfizer in discussions with regulators; no timeline for approval.